Abstract
Aim
To evaluate the epidemiology of male breast cancer (MBC) in Italy and to describe incidence and survival data in relation to age, morphology, year of incidence, geographic area, and possible association with other cancers compared with female BC.
Methods
Cases were extracted from 40 Italian Cancer Registries. Standardized incidence rates (SIR), age-specific rates, and 5-year survival were calculated. The association with second tumors was also evaluated. All data were compared with data from female BCs.
Results
In the 2000–2014 period, 2175 new cases of MBC were registered, with an SIR of 1.7 × 100,000. The incidence showed a slight upward trend and increased with increasing age. The 5-year survival was 82% in the first two periods (2000–2004, 2005–2009), lower than in females (87%). The most frequent morphology was the ductal carcinoma (84%). Stage at diagnosis was 39.5% stage I, 33.1% stage II, 20.9% in stage III, and 6.4% in stage IV. Concerning receptor status, 96.4% had ER+ and 82.5% PR+; 46.5% had high Ki67 and 14.7% HER2 amplified. The risk of BC increased if the man had already had a previous tumor in any site (excess absolute risk, EAR = 2.7) and especially if he had had prostate cancer (EAR = 5.1). Instead, males with a previous diagnosis of BC had an increased risk of testicular, kidney and lung cancer.
Conclusions
MBC requires more attention in terms of diagnosis and treatment as clinicians tend to follow the guidelines that have been developed for female BC management.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28(2):232–9.
AIOM, AIRTUM, Fondazione AIOM, PASSI. I numeri del cancro in Italia 2018, Intermedia Editore; 2018.
Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer—a case–control study from Scandinavia. Acta Oncol. 2001;40(4):467–71.
Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22(4):735–42 (review).
Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114–222.
Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother. 2007;8(2):193–202 (review).
https://www.registri-tumori.it/cms/. Accessed 7 Jan 2020.
Buzzoni C, Crocetti E, Bella F, Bonelli L, Caldarella A, Castaing M, et al. I tumori in Italia—Rapporto 2013, Tumori multipli. Epidemiol Prev. 2013;37(4–5 Suppl 1):1–152.
Coviello V, Buzzoni C, Fusco M, Barchielli A, Cuccaro F, De Angelis R, AIRTUM Working Group, et al. Survival of cancer patients in Italy. Epidemiol Prev. 2017;41(2 Suppl 1):1–244. https://doi.org/10.19191/EP17.2S1.P001.017.
Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer. 2009;45(18):3166–71.
Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405–17.
Rizzolo P, Zelli V, Silvestri V, Valentini V, Zanna I, Bianchi S, et al. Insight into genetic susceptibility to male breast cancer by multigene panel testing: results from a multicenter study in Italy. Int J Cancer. 2019;145(2):390–400.
https://seer.cancer.gov/data/. Accessed 7 Jan 2020.
Silvestri V, Zelli V, Valentini V, Rizzolo P, Navazio AS, Coppa A, et al. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Cancer. 2017;123(2):210–8.
Humphries MP, Sundara Rajan S, Honarpisheh H, Cserni G, Dent J, Fulford L, et al. Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Sci Rep. 2017;28(7):45293.
Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, et al. A possible role of FANCM mutations in male breast cancer susceptibility: results from a multicenter study in Italy. Breast. 2018;38:92–7.
Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, et al. Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol. 2013;24(Suppl 8):viii75–viii82.
Romaguera D, Lavedan E, Molinuevo A, de Batlle J, Mendez M, Moreno V, et al. Adherence to nutrition-based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the MCC-Spain case–control study. Int J Cancer. 2017;141(1):83–93. https://doi.org/10.1002/ijc.30722(Epub 2017 Apr 21).
Acknowledgements
The authors thank the participating cancer registries for collecting and preparing the data as part of their essential role in cancer control.
Funding
This research has been partially funded by the Emilia-Romagna Regional health Authority, DGR.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mangone, L., Ferrari, F., Mancuso, P. et al. Epidemiology and biological characteristics of male breast cancer in Italy. Breast Cancer 27, 724–731 (2020). https://doi.org/10.1007/s12282-020-01068-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12282-020-01068-1